886-PerturbFate:解析黑色素瘤耐药性趋同调控机制 episode artwork

EPISODE · May 2, 2026 · 22 MIN

886-PerturbFate:解析黑色素瘤耐药性趋同调控机制

from 聊聊Sci

本文介绍了由 Zihan Xu 等人研发的新型高通量单细胞多组学筛选平台 PerturbFate。该平台通过结合 CRISPRi 干扰技术与组合索引测序,能够同时监测单细胞内的染色质可及性、新生转录本及稳态转录组动态。研究人员利用该技术解析了黑色素瘤细胞对药物 vemurafenib 产生耐药性的分子机制,识别出一种受 AP-1 和 TEAD 等转录因子协同驱动的共同去分化细胞状态。此外,研究深入剖析了 Mediator 复合物 不同亚基在调节细胞状态转换中的功能差异,揭示了 VEGFC 作为趋同调控节点在介导多种基因扰动导致耐药中的核心作用。总之,PerturbFate 为揭示复杂疾病表型背后的核心基因调控网络提供了强有力的技术支撑。References: Xu Z, Lu Z, Ugurbil A, et al. Mapping convergent regulators of melanoma drug resistance by PerturbFate[J]. Nature, 2026: 1-11.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published May 2, 2026

Embed this episode

Ready to play

886-PerturbFate:解析黑色素瘤耐药性趋同调控机制

0:00 22:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 22 minutes long.

When was this 聊聊Sci episode published?

This episode was published on May 2, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!